Different review opinions stated the capability of the small molecule theragnostic to combine imaging and treatment at the same time, presenting great promise to treat and diagnose in vivo prion diseases through its ability to bind with PrPC and consequently prevent prion conversion [52,53,54]. Here, PRNP is linked to prion disease.